In-vitro activity of rifabutin against rifampicin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations

Clinical Microbiology and Infection

Volumn 10, Issue 7, 2004, Pages 662-665

  Cavusoglu, Cengiz ^a   Karaca Derici, Y ^a   Bilgic, A ^a  

^a EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Myobacterium tuberculosis; Resistance; Rifabutin; Rifampicin; rpoB

Indexed keywords

RIFABUTIN; RIFAMPICIN; RNA POLYMERASE BETA SUBUNIT;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CODON; CORRELATION ANALYSIS; GENE MUTATION; IN VITRO STUDY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL;

MYCOBACTERIUM; MYCOBACTERIUM TUBERCULOSIS;

EID: 4043181220     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2004.00917.x     Document Type: Article

References (20)

1. Ramaswamy S, Musser JM. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tubercle Lung Dis 1998; 79: 3-29.
2. Zhang Y, Telenti A. Genetics of drug resistance in Mycobacterium tuberculosis. In: Hatfull GF, Jacobs WR, eds. Molecular genetics of mycobacteria. Washington, DC American Society for Microbiology, 2000; 235-254.
3. Dooley SW, Jarvis WR, Martone WJ, Snider DE. Multidrug-resistant tuberculosis. Ann Intern Med 1992; 117: 257-259.
4. Frieden TR, Sterling T, Pablo-Mendez A, Kilburn JO, Cauthen GM, Dooley SW. The emergence of drug-resistant tuberculosis in New York city. N Engl J Med 1993; 328: 521-526.
5. Telenti A, Imboden P, Marchesi F et al. Detection of rifampin-resistance mutations in Mycobacterium tuberculosis. Lancet 1993; 341: 647-650.
6. Matsiota-Bernard P, Vrioni G, Marinis E. Characterization of rpoB mutations in rifampin-resistant clinical Mycobacterium tuberculosis isolates from Greece. J Clin Microbiol 1998; 36: 20-23.
7. Dickinson JM, Mitchinson DA. In vitro activity of new rifamycins against rifampicin-resistant M. tuberculosis and MAIS-complex mycobacteria. Tubercle 1987; 68: 177-182.
8. Farr BM. Rifamycins. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases. Philadelphia: Churchill Livingstone, 2000; 348-360.
9. Musser JM. Antimicrobial agent resistance in mycobacteria: molecular genetic insights. Clin Microbiol Rev 1995; 8: 496-514.
10. Bodmer T, Zurcher G, Imboden P, Telenti A. Mutation position and type of substitution in the β-subunit of the RNA polymerase influence in-vitro activity of rifamycins in rifampicin-resistant Mycobacterium tuberculosis. J Antimicrob Chemother 1995; 35: 345-348.
11. Uzun M, Erturan Z, Ang O. Investigation of cross-resistance between rifampin and rifabutin in Mycobacterium tuberculosis complex strains. Int J Tuberc Lung Dis 2002; 6: 164-165.
12. Williams DL, Spring L, Collins L et al. Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 1998; 42: 1853-1857.
13. Yang B, Koga H, Ohno H et al. Relationship between antimycobacterial activities of rifampicin, rifabutin and KRM 1648 and rpoB mutations of Mycobacterium tuberculosis. J Antimicrob Chemother 1998; 42: 621-628.
14. Yuen LKW, David L, Coloe PJ. Bacteriological and molecular analysis of rifampin-resistant Mycobacterium tuberculosis strains isolated in Australia. J Clin Microbiol 1999; 37: 3844-3850.
15. National Committee for Clinical Laboratory Standards. Susceptibility testing of mycobacteria, Nocardia, and other aerobic actinomycetes, 2nd edn. Tentative standard. M24-T2. Wayne, PA: NCCLS, 2002.
16. Cavusoglu C, Hilmioglu S, Guneri S, Bilgic A. Characterization of rpoB mutations in rifampin-resistant clinical isolates of Mycobacterium tuberculosis from Turkey by DNA sequencing and line probe assay. J Clin Microbiol 2002; 40: 4435-4438.
17. Hwang HY, Chang CY, Chang LL, Chang SF, Chang YH, Chen YJ. Characterization of rifampin resistant Mycobacterium tuberculosis in Taiwan. J Med Microbiol 2003; 52: 239-245.
18. Moghazeh SL, Pan X, Arain T, Stover CK, Musser JM, Kreiswirth BN. Comparative antimycobacterial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations. Antimicrob Agents Chemother 1996; 40: 2655-2657.
19. Ohno H, Koga H, Kohno S, Tashiro T, Hara K. Relationship between rifampin MICs for and rpoB mutations of Mycobacterium tuberculosis strains isolated in Japan. Antimicrob Agents Chemother 1996; 40: 1053-1056.
20. Hui J, Gordon N, Kajioka R. Permeability barrier to rifampin in mycobacteria. Antimicrob Agents Chemother 1977; 11: 773-779.